📊 CNMD Key Takeaways
Is CONMED Corp (CNMD) a Good Investment?
CNMD demonstrates solid operational cash generation (FCF margin 11%) and healthy liquidity (2.14x current ratio), but faces significant headwinds including flat revenue growth, sharp net income decline (-64.5% YoY), and weakening profitability margins (net margin 3.4%). The company's leverage remains manageable at 0.81x debt-to-equity, though deteriorating earnings quality requires monitoring of operational execution and market demand.
CONMED’s fundamentals show a mixed but weakening profile: revenue was flat while net income and diluted EPS fell sharply, indicating significant pressure below the gross profit line. Although the company still generates solid free cash flow and maintains acceptable liquidity, low net margins, weak returns on capital, and only moderate interest coverage point to constrained earnings quality and elevated balance sheet risk.
Why Buy CONMED Corp Stock? CNMD Key Strengths
- Strong free cash flow generation of $150.9M with 11% FCF margin indicates robust operational efficiency
- Solid liquidity position with 2.14x current ratio and quick ratio of 1.01x supports financial stability
- Healthy gross margin of 54.6% reflects underlying product competitiveness and pricing power in medical device market
- Moderate leverage at 0.81x debt-to-equity with 3.3x interest coverage provides financial flexibility
- Solid free cash flow generation with $150.88M of FCF and an 11.0% FCF margin
- Healthy gross margin of 54.6%, showing underlying product-level profitability
- Adequate liquidity with a 2.14x current ratio and 1.01x quick ratio
CNMD Stock Risks: CONMED Corp Investment Risks
- Revenue stagnation at 1.4B with 0% YoY growth signals market saturation or competitive pressure in electromedical apparatus segment
- Severe net income decline of -64.5% YoY and sharp drop in diluted EPS to $1.51 indicate operational challenges or non-recurring charges requiring clarification
- Deteriorating net margin of 3.4% reflects compressed profitability despite stable gross margins, suggesting rising operating expenses or tax burden
- Low ROE of 4.6% and ROA of 2.0% indicate inefficient capital deployment relative to equity and asset base
- Minimal cash position of $40.8M relative to $1.3B liabilities limits financial flexibility for strategic investments or downturns
- Net income declined 64.5% year over year despite flat revenue, signaling major earnings deterioration
- Leverage remains meaningful with $834.23M of long-term debt and only 3.3x interest coverage
- Profitability is weak with a 3.4% net margin, 4.6% ROE, and 2.0% ROA
Key Metrics to Watch
- Revenue growth acceleration - must demonstrate organic growth resumption to validate market demand
- Net income trajectory - critical to understand whether -64.5% decline is temporary or structural
- Operating margin stability - monitor if 7.5% margin holds or continues compressing
- Free cash flow sustainability - validate that $150.9M FCF can be maintained with current capital efficiency
- Debt reduction progress - track deleveraging toward lower debt-to-equity given low profitability
- Operating margin and net income recovery
- Interest coverage and long-term debt reduction
CONMED Corp (CNMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.14x current ratio provides a solid financial cushion.
CNMD Profit Margin, ROE & Profitability Analysis
CNMD vs Healthcare Sector: How CONMED Corp Compares
How CONMED Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CONMED Corp Stock Overvalued? CNMD Valuation Analysis 2026
Based on fundamental analysis, CONMED Corp shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CONMED Corp Balance Sheet: CNMD Debt, Cash & Liquidity
CNMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CONMED Corp's revenue has grown significantly by 36% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.04 reflects profitable operations.
CNMD Revenue Growth, EPS Growth & YoY Performance
CNMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $316.7M | $2.9M | $0.09 |
| Q2 2025 | $332.1M | $21.4M | $0.69 |
| Q1 2025 | $312.3M | $6.0M | $0.19 |
| Q3 2024 | $304.6M | $15.8M | $0.50 |
| Q2 2024 | $317.7M | $13.7M | $0.43 |
| Q1 2024 | $295.5M | $1.8M | $0.06 |
| Q3 2023 | $275.1M | $15.8M | $0.50 |
| Q2 2023 | $277.2M | $13.7M | $0.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CONMED Corp Dividends, Buybacks & Capital Allocation
CNMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CONMED Corp (CIK: 0000816956)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CNMD
What is the AI rating for CNMD?
CONMED Corp (CNMD) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CNMD's key strengths?
Claude: Strong free cash flow generation of $150.9M with 11% FCF margin indicates robust operational efficiency. Solid liquidity position with 2.14x current ratio and quick ratio of 1.01x supports financial stability. ChatGPT: Solid free cash flow generation with $150.88M of FCF and an 11.0% FCF margin. Healthy gross margin of 54.6%, showing underlying product-level profitability.
What are the risks of investing in CNMD?
Claude: Revenue stagnation at 1.4B with 0% YoY growth signals market saturation or competitive pressure in electromedical apparatus segment. Severe net income decline of -64.5% YoY and sharp drop in diluted EPS to $1.51 indicate operational challenges or non-recurring charges requiring clarification. ChatGPT: Net income declined 64.5% year over year despite flat revenue, signaling major earnings deterioration. Leverage remains meaningful with $834.23M of long-term debt and only 3.3x interest coverage.
What is CNMD's revenue and growth?
CONMED Corp reported revenue of $1.4B.
Does CNMD pay dividends?
CONMED Corp pays dividends, with $24.7M distributed to shareholders in the trailing twelve months.
Where can I find CNMD SEC filings?
Official SEC filings for CONMED Corp (CIK: 0000816956) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CNMD's EPS?
CONMED Corp has a diluted EPS of $1.51.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CNMD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, CONMED Corp has a SELL rating with 74% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CNMD stock overvalued or undervalued?
Valuation metrics for CNMD: ROE of 4.6% (sector avg: 15%), net margin of 3.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CNMD stock in 2026?
Our dual AI analysis gives CONMED Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CNMD's free cash flow?
CONMED Corp's operating cash flow is $170.7M, with capital expenditures of $19.8M. FCF margin is 11.0%.
How does CNMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 3.4% (avg: 12%), ROE 4.6% (avg: 15%), current ratio 2.14 (avg: 2).